Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: luis a. garcia who wrote (896)	2/3/1998 2:11:00 AM
From: John Zwiener	Read Replies (2) \| Respond to of 1115

Luis, there is just enough here to see a good price increase, although the spector of the mysterious healthmed may limit the price. Since many are watching this company, if only to see what the deal is about, we may get some idea of the quality of the deal by the reaction of the stock price. But until then, it's possible that we may see 5 to 10 dollars/share based on these new P values. A 2 day improvement over placebo is quite possible. With other antiherpes drugs having a $2 billion market worldwide, and being only marginally effective (plus working be interfering with DNA), and tending to be irritating in their own right, it's possible that Lidakol could capture the majority of the herpes market. I also tend to be concerned about the healthmed deal. They look like they want too much for the loan. My first impulse is to go to another lender. Need more imput. Luis, check your brake fluid, not the transmission fluid. I can report I have a transmission leak. Later Luis, John.